Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies

PLoS Medicine

Volumn 8, Issue 9, 2011, Pages

  McGettigan, Patricia ^a   Henry, David ^b,c,d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; PIROXICAM; ROFECOXIB; VALDECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DICLOFENAC; HUMANS; IBUPROFEN; NAPROXEN;

EID: 80053307147     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001098     Document Type: Review

References (36)

1. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, et al. (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735-741.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528.
3. Bertagnolli M, Eagle CJ, Zauber AG, Redston M, Solomon SD, et al. (2000) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884.
4. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzales-Perez A, (2004) Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109: 3000-3006.
5. Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, et al. Solomon DH (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068-2073.
6. Henry D, Lim LL, García Rodríguez LA, Perez Gutthann S, Carson JL, et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312: 1563-1566.
7. McGettigan P, Henry D, (2006) Cardiovascular risk and inhibition of cylcooxygenase: a systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase-2. JAMA 296: 1633-1644.
8. Fosbol EL, Folke F, Gislason GH, Jacobsen S, Rasamussen JN, et al. (2010) Cause-specific cardiovascular risk associated with non-steroidal anti-inflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 3: 395-405 doi:10.1161/circoutcomes.109.861104.
9. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302-1308.
10. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342: c7086 doi:10.1136/bmj.c7086.
11. García Rodríguez LA, González-Pérez A, Bueno H, Hwa J, (2011) NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS ONE 6: e16780 doi:10.1371/journal.pone.0016780.
12. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA, (2006) Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol 98: 266-274.
13. Clinical Trial Service Unit and Epidemiological Studies Unit (2009) Coxib and traditional NSAID trialists' (CNT) collaboration. Oxford: University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit. Available: http://www.ctsu.ox.ac.uk/projects/cnt. Accessed 6 August 2011.
14. Wells GA, Shea B, O'Connell D, Peterson P, Welch V, et al. (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 6 August 2011.
15. Altman DG, Bland JM, (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
16. Hutchon DJR, (2005) Calculations for comparing two estimated relative risks [computer program]. Available: http://www.hutchon.net/CompareRR.htm. Accessed 6 August 2011.
17. Anonymous (2011) Etoricoxib. Wikipedia: the free encyclopedia. Available: http://en.wikipedia.org/wiki/Etoricoxib. Accessed 6 August 2011.
18. Barozzi N, Tett SE, (2007) What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 16: 1184-1191.
19. Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, et al. (2004) Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 50: 598-606.
20. Schneeweiss S, (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15: 291-303.
21. Lévesque LE, Brophy JM, Zhang B, (2006) Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 174: 1563-1569 doi:10.1503/cmaj.051679.
22. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, et al. (2006) NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27: 1657-1663.
23. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation 117: 2104-2113.
24. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R, (2006) Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J R Soc Med 99: 132-140.
25. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771-1781.
26. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, et al. (2005) Implications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091.
27. Lúcio M, Ferreira H, Lima JL, Reis S, (2006) Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity. Med Chem 2: 447-456.
28. Anonymous (2011) Indomethacin: drug information provided by Lexi-Comp. The Merck Manual for Health Care Professionals. Available: http://www.merckmanuals.com/professional/lexicomp/indomethacin.html. Accessed 6 August 2011.
29. Thompson M, Percy JS, (1966) Further experience with indomethacin in the treatment of rheumatic disorders. BMJ 1: 80-83.
30. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, et al. (1998) Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 37: 937-945.
31. Olsen AMS, Fosbol EL, Lindhardsen J, Folke F, Charlot M, et al. (2011) Duration of treatment with non-steroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123: 2226-2235.
32. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RSJ, et al. (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357: 360-369.
33. Grosser T, Fries S, Fitzgerald GA, (2006) Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15.
34. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D, (2003) Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52: 1265-1270.
35. Golder S, Loke YK, Bland M, (2011) Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 8: e10011026 doi:10.1371/journal.pmed.1001026.
36. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, et al. (2001) Cyclo-oxygenase inhibitors and the anti-platelet effect of aspirin. New Engl J Med 345: 1809-1817.